RAC 2.92% $1.94 race oncology ltd

Ann: First Patient Dosed in Phase 1b/2 AML Trial, page-11

  1. 120 Posts.
    lightbulb Created with Sketch. 84
    Although never marketed, bisantrene was approved for the treatment of AML in France in 1991 under the name Zantrene
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.